JP2020514383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514383A5 JP2020514383A5 JP2019551984A JP2019551984A JP2020514383A5 JP 2020514383 A5 JP2020514383 A5 JP 2020514383A5 JP 2019551984 A JP2019551984 A JP 2019551984A JP 2019551984 A JP2019551984 A JP 2019551984A JP 2020514383 A5 JP2020514383 A5 JP 2020514383A5
- Authority
- JP
- Japan
- Prior art keywords
- drug composition
- compound
- weight
- protein
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 26
- 229940079593 drug Drugs 0.000 claims 26
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims 6
- 108091006905 Human Serum Albumin Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- -1 carboxylate anion Chemical class 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 238000002296 dynamic light scattering Methods 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000962 organic group Chemical group 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 125000000743 hydrocarbylene group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 229940035893 uracil Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762475185P | 2017-03-22 | 2017-03-22 | |
| US62/475,185 | 2017-03-22 | ||
| PCT/US2018/023578 WO2018175592A1 (en) | 2017-03-22 | 2018-03-21 | Modified oligonucleotides and therapeutic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514383A JP2020514383A (ja) | 2020-05-21 |
| JP2020514383A5 true JP2020514383A5 (enExample) | 2021-04-30 |
Family
ID=63586170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551984A Pending JP2020514383A (ja) | 2017-03-22 | 2018-03-21 | 修飾オリゴヌクレオチドおよびその治療上の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200046846A1 (enExample) |
| EP (1) | EP3600439A4 (enExample) |
| JP (1) | JP2020514383A (enExample) |
| KR (1) | KR20190123351A (enExample) |
| CN (1) | CN110636865A (enExample) |
| AU (1) | AU2018237139A1 (enExample) |
| CA (1) | CA3057292A1 (enExample) |
| SG (1) | SG11201908771YA (enExample) |
| WO (1) | WO2018175592A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250270248A1 (en) * | 2020-09-16 | 2025-08-28 | Astrazeneca Ab | Oligonucleotides conjugated to fatty acids |
| CN117980003A (zh) * | 2021-09-10 | 2024-05-03 | 嘉德治疗有限责任公司 | 核酸的脂肪酸缀合物 |
| WO2025028656A1 (ja) * | 2023-08-02 | 2025-02-06 | 日東電工株式会社 | オリゴヌクレオチドを製造する方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0821001A4 (en) * | 1995-03-31 | 2002-07-17 | Drug Delivery System Inst Ltd | AMIDITY DERIVATIVES AND OLIGONUCLEOTIDE DERIVATIVES |
| US8969543B2 (en) * | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
| WO2007112414A2 (en) * | 2006-03-27 | 2007-10-04 | Isis Pharmaceuticals, Inc. | Conjugated double strand compositions for use in gene modulation |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | ｓｉＲＮＡ 접합체 및 그 제조방법 |
| GB0910723D0 (en) * | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| CN103649311A (zh) * | 2011-06-03 | 2014-03-19 | 国立大学法人北海道大学 | 寡核苷酸衍生物、包含寡核苷酸衍生物的治疗用医药组合物及诊断用医药组合物、以及miRNA机能抑制用寡核苷酸衍生物 |
| RU2599449C1 (ru) * | 2011-12-15 | 2016-10-10 | Байонир Корпорейшн | Новые конъюгаты олигонуклеотидов и их применение |
| DK3019200T3 (da) * | 2013-07-11 | 2022-06-20 | Alnylam Pharmaceuticals Inc | Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf |
| CN105792851B (zh) * | 2013-09-13 | 2023-10-10 | 斯克利普斯研究所 | 修饰的治疗剂及其组合物 |
| AU2014364589B2 (en) * | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| JP6773677B2 (ja) * | 2015-03-17 | 2020-10-21 | アローヘッド ファーマシューティカルズ インコーポレイテッド | 改善されたジスルフィド含有アルキン連結剤 |
| MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
| WO2017030973A1 (en) * | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| AU2016326392B2 (en) * | 2015-09-22 | 2021-02-11 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
-
2018
- 2018-03-21 AU AU2018237139A patent/AU2018237139A1/en not_active Abandoned
- 2018-03-21 JP JP2019551984A patent/JP2020514383A/ja active Pending
- 2018-03-21 EP EP18770600.7A patent/EP3600439A4/en not_active Withdrawn
- 2018-03-21 WO PCT/US2018/023578 patent/WO2018175592A1/en not_active Ceased
- 2018-03-21 CA CA3057292A patent/CA3057292A1/en not_active Abandoned
- 2018-03-21 KR KR1020197030864A patent/KR20190123351A/ko not_active Ceased
- 2018-03-21 US US16/492,642 patent/US20200046846A1/en not_active Abandoned
- 2018-03-21 SG SG11201908771Y patent/SG11201908771YA/en unknown
- 2018-03-21 CN CN201880026265.5A patent/CN110636865A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7355758B2 (ja) | ケモカイン受容体調節剤及びその使用 | |
| US10604526B2 (en) | Chemokine receptor modulators and uses thereof | |
| ES2707534T3 (es) | Compuestos útiles como inmunomoduladores | |
| ES2247371T3 (es) | Agonistas del receptor a3 de adenosina. | |
| JP2019511491A5 (enExample) | ||
| CN1424913A (zh) | 抗病毒前体药物 | |
| TW201902517A (zh) | Ｒａｆ降解結合物化合物 | |
| JP7212683B2 (ja) | 抗がん剤としての環状ジヌクレオチド | |
| CN101932310B (zh) | 制备基于官能两亲分子或者大分子的纳米颗粒的方法和其用途 | |
| RU2016146819A (ru) | Композиции и способы модулирования экспрессии рецептора гормона роста | |
| JP2020514383A5 (enExample) | ||
| JP2023541427A (ja) | 骨格筋送達プラットフォーム及び使用方法 | |
| TNSN07154A1 (en) | Purine derivatives for use as adenosin a-2a receptor agonists | |
| JP2012528867A5 (enExample) | ||
| JP2023541415A (ja) | 治療薬の送達用脂質複合体 | |
| JP2013518036A5 (enExample) | ||
| US20040116376A1 (en) | Adenosine A3 receptor agonists | |
| JP2015517565A5 (enExample) | ||
| WO2006030217A2 (en) | Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs | |
| JP2025512963A (ja) | ケモカイン受容体モジュレータ及びその使用 | |
| JP6358661B2 (ja) | 界面活性剤様化合物 | |
| JP2006520359A5 (enExample) | ||
| EP1663181A2 (en) | Protein binding compounds | |
| US20250122208A1 (en) | Chemokine receptor modulators and uses thereof | |
| JPWO2022272043A5 (enExample) |